Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C– a systematic review and meta-analysis

Direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection might pose a risk for hepatitis B virus (HBV) reactivation in patients coinfected with chronic or resolved HBV infection. The need for HBV antiviral prophylaxis during DAA treatment remains controversial. We aimed to analyse the absolute risk of HBV reactivation in patients with active or resolved HBV infection treated with DAAs for HCV infection.

• Source: Thelancet
• 504
• January 24, 2018